Cryo Cell International Inc (CCEL)

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American

Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem...

Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks

Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank, has been granted renewed...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results

Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world’s first private cord blood bank to separate and store stem...

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership

Form 8-K - Current report

Cryo-Cell Receives NYSE American Continued Listing Notice

Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025

Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities